Iterum Therapeutics (NASDAQ:ITRM – Get Free Report) and Veru (NASDAQ:VERU – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, institutional ownership, analyst recommendations and risk.
Risk & Volatility
Iterum Therapeutics has a beta of 2.96, meaning that its stock price is 196% more volatile than the S&P 500. Comparatively, Veru has a beta of -1.2, meaning that its stock price is 220% less volatile than the S&P 500.
Institutional and Insider Ownership
9.2% of Iterum Therapeutics shares are owned by institutional investors. Comparatively, 47.2% of Veru shares are owned by institutional investors. 2.0% of Iterum Therapeutics shares are owned by insiders. Comparatively, 14.2% of Veru shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Analyst Recommendations
This is a summary of recent ratings and recommmendations for Iterum Therapeutics and Veru, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Iterum Therapeutics | 1 | 2 | 0 | 0 | 1.67 |
| Veru | 1 | 0 | 3 | 0 | 2.50 |
Veru has a consensus price target of $24.50, suggesting a potential upside of 1,077.88%. Given Veru’s stronger consensus rating and higher possible upside, analysts plainly believe Veru is more favorable than Iterum Therapeutics.
Valuation and Earnings
This table compares Iterum Therapeutics and Veru”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Iterum Therapeutics | $390,000.00 | 4.10 | -$24.77 million | ($0.75) | -0.04 |
| Veru | N/A | N/A | -$22.73 million | ($0.69) | -3.01 |
Veru has lower revenue, but higher earnings than Iterum Therapeutics. Veru is trading at a lower price-to-earnings ratio than Iterum Therapeutics, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Iterum Therapeutics and Veru’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Iterum Therapeutics | N/A | N/A | -65.54% |
| Veru | N/A | -47.58% | -35.83% |
Summary
Veru beats Iterum Therapeutics on 8 of the 12 factors compared between the two stocks.
About Iterum Therapeutics
Iterum Therapeutics plc (NASDAQ:ITRM) is an Ireland-based pharmaceutical company focused on developing and commercializing anti-infective therapies for infections caused by drug-resistant bacteria. The company’s lead product is sulopenem, a penem-class antibiotic designed to provide activity against a broad range of pathogens. In 2024, the U.S. Food and Drug Administration approved Orlynvah, an oral combination of sulopenem etzadroxil and probenecid, for the treatment of uncomplicated urinary tract infections in adult women when alternative oral antibacterial treatments are not suitable.
About Veru
Veru Inc. is a biopharmaceutical company focused on developing medicines for metabolic diseases and cancer. Its research programs include enobosarm, which is being studied to help preserve muscle during weight loss associated with GLP-1 medicines, as well as candidates investigated for breast and prostate cancer. The company has also developed sabizabulin, an investigational drug studied for cancer treatment. These medicines remain development-stage products; Veru’s clinical programs and priorities may change as research progresses.
Receive News & Ratings for Iterum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iterum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
